Panavance Therapeutics
  • Our Science
    • Pipeline
    • About GP-2250
  • About
    • About Panavance
    • Leadership
    • Board of Directors
    • Advisors & Collaborators
    • Contact Panavance
  • Resources
    • Publications
    • Brochures
    • Videos
    • Press Releases
    • Events
  • Participate

Let’s engage.

Substance GP-2250 as a new therapeutic agent for malignant peritoneal mesothelioma – a 3-D in vitro study

June 20, 2022 / 0 Minute Read

panavance therapeutics

  • Our Science
  • About
  • Resources
  • Participate
  • LinkedIn
  • Twitter
  • Facebook

+1.610.922.1910

Copyright © 2024 Panavance Therapeutics Inc.